Low Dose Abilify Ineffective as Adjunct for MDD

The Carlat Psychiatry Report, Volume 10, Number 7&8, July 2012

Glen Spielmans, PhD

Associate professor of psychology, Metropolitan State University, St. Paul, MN

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Augmentation of antidepressants with antipsychotics has become a common practice, and aripiprazole (Abilify) has been FDA-approved at doses from 2 mg/day to 15 mg/day for this purpose. In a recent report, 225 patients with major depressive disorder (MDD) who had failed one to four antidepressant trials were studied to determine whether low dose Abilify really works.

You can't view details of this content, please login or buy subscription here